



FFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Lusso et al. Art Unit: 1648
Serial No.: 10/524,549 Examiner: Li, Bao Q
Filed: September 13, 2005
Title: *Pharmaceutical Composition Comprising an HIV Envelope Protein and CD4*

Mail Stop Amendment

United States Patent and Trademark Office
Customer Service Window
Randolph Building
401 Dulany Street
Alexandria VA 22314

RESPONSE TO RESTRICTION REQUIREMENT

Applicants thank the Examiner for vacating the previous Office Action which inadvertently excluded claims 23-31 in the restricted groups.

In response to the outstanding Restriction Requirement mailed June 19, 2007, Applicants elect Group III, claims 23-28, without traverse.

Applicants further elect for examination, the species where the polynucleotide encoding HIV envelope protein and polynucleotide encoding CD4 receptor are separate vectors. Applicants also elect for examination the species where the CD4 receptor is human CD4. Claims 23-28 read on the elected species.

Should any further fees be required by the present Reply, the Commissioner is hereby authorized to debit or credit Deposit Account **19-4293**.

Date: 7-18-07

Customer No. 27890
Steptoe & Johnson LLP
1330 Connecticut Avenue, NW
Washington, DC 20036-1795
Phone: 202-429-6748
Fax: 202-429-3902

Respectfully submitted,

Harold H. Fox
Reg. No. 41,498